scholarly journals Reading the signs: Microrips as a prognostic sign for impending RPE tear development

2015 ◽  
Vol 93 (7) ◽  
pp. e600-e602 ◽  
Author(s):  
Christoph R. Clemens ◽  
Florian Alten ◽  
Nicole Eter
Keyword(s):  
2021 ◽  
Vol 77 (18) ◽  
pp. 3150
Author(s):  
Max Ruge ◽  
Joanne Michelle D. Gomez ◽  
Jeanne Du Fay de Lavallaz ◽  
J. Alan Simmons ◽  
Jessica Canzolino ◽  
...  

2018 ◽  
Vol 2018 ◽  
pp. 1-8 ◽  
Author(s):  
Jae Hui Kim ◽  
Young Suk Chang ◽  
Jong Woo Kim ◽  
Chul Gu Kim ◽  
Dong Won Lee

Purpose. To investigate the incidence and timing of prechoroidal cleft development and its association with visual prognosis in type 3 neovascularization. Methods. This retrospective study included 166 eyes that were diagnosed with type 3 neovascularization. All eyes were treated with antivascular endothelial growth factor therapy. The incidence and timing of prechoroidal cleft development were evaluated. Best-corrected visual acuity (BCVA) at diagnosis and at final follow-up was compared between eyes with (cleft group) and without (no-cleft group) prechoroidal cleft. The incidence of retinal pigment epithelium (RPE) tear and subretinal hemorrhage was also compared between the two groups. Results. During the mean 39.7 ± 18.5 months of follow-up, prechoroidal cleft developed in 37 eyes (22.3%) at an average of 14.6 ± 10.4 months. The BCVA at final follow-up was significantly worse in the cleft group than in the no-cleft group (P=0.024), whereas the difference was not significant at diagnosis (P=0.969). The incidence of RPE tear (P=0.002) and subretinal hemorrhage (P<0.001) was significantly higher in the cleft group. Conclusions. Prechoroidal cleft is a frequently observed finding during the treatment course of type 3 neovascularization. Eyes with prechoroidal cleft are at high risk of RPE tear or subretinal hemorrhage and subsequently associated with poor prognosis.


2010 ◽  
Vol 92 (6) ◽  
pp. e9-e10 ◽  
Author(s):  
Jonathan Evans ◽  
Chris Craig

Often believed to be a poor prognostic sign, hepatoportal venous gas (HPVG) has been associated with massive intra-abdominal sepsis. It is more frequently detected as computed tomography imaging techniques improve. A patient presenting with radiological evidence of HPVG is discussed and the literature reviewed. This study aims to highlight the increasing understanding that HPVG may sometimes follow a more indolent course than previously believed. Patient assessment is the key in selecting those who need urgent laparotomy.


1987 ◽  
Vol 26 (7) ◽  
pp. 361-365 ◽  
Author(s):  
Margery A. Heneghan ◽  
Richard Sosulski ◽  
Margarita B. Alarcon

PEDIATRICS ◽  
1956 ◽  
Vol 17 (2) ◽  
pp. 221-229
Author(s):  
Judson J. Van Wyk ◽  
Melvin M. Grumbach ◽  
Thomas H. Shepard ◽  
Lawson Wilkins

During the past 10 years thiouracil and propylthiouracil have been used to treat all children with hyperthyroidism in the Harriet Lane Home Endocrine Clinic. Follow-ups are available on 16 children whose disease began before 13 years of age. Eight of this group are now in a period of prolonged remission; 4 have required subsequent surgery, and 4 are still under treatment. The occurrence of adolescence has not been found to induce a relapse in any child who was previously in remission. Reduction in the size of the goiter while the patient is receiving treatment has been found to be the best prognostic sign. The combined use of thyroid with antithyroid drugs has caused involution of the gland in those patients whose goiters remained large after treatment with propylthiouracil alone. The ultimate value of this combined treatment remains to be determined. It is recommended that surgery be reserved for those children who are sensitive to antithyroid drugs, who fail to co-operate or cannot be followed closely. In the remainder, treatment with antithyroid drugs should be continued until there is substantial reduction in the size of the gland. A period of 2 years of continuous therapy is suggested as the minimal period of treatment.


Cardiology ◽  
1981 ◽  
Vol 68 (2) ◽  
pp. 78-83 ◽  
Author(s):  
M. Hayet ◽  
J.J. Kellermann

1983 ◽  
Vol 1 (7) ◽  
pp. 416-420 ◽  
Author(s):  
D L Trump ◽  
S A Anderson

Ninety-six patients who received cytotoxic chemotherapy for germ cell neoplasms of the testis were studied. Painful gynecomastia developed in eight patients (8%) between 6 and 24 weeks after the initiation of cytotoxic therapy (mean 18 wk). Serum content of the beta subunit of human chorionic gonadotropin was normal in each patient when gynecomastia developed. Gynecomastia occurred following cytotoxic therapy for advanced disease in seven patients, and one patient was receiving adjunctive drug therapy for stage I disease. Six of the seven patients with advanced disease were in complete remission when gynecomastia developed; survival was superior in patients who developed treatment-related gynecomastia compared to those patients who did not (p less than 0.05). Gynecomastia may occur in adult males after cytotoxic therapy for testis cancer; such gynecomastia does not necessarily indicate recurrent malignancy and may be a favorable prognostic sign.


2001 ◽  
Vol 87 (7) ◽  
pp. 924-926 ◽  
Author(s):  
Josephine Chiu ◽  
Shaul Atar ◽  
Robert J. Siegel

Sign in / Sign up

Export Citation Format

Share Document